Correction to: Nature Medicine https://doi.org/10.1038/s41591-021-01444-0, published online 2 August 2021.
In the version of this article initially published, there were textual errors in the abstract and main text. In the penultimate sentence of the abstract, the text “immune-related AEs (irAEs) (39.7 versus 18.9%) and grade ≥3 irAEs (7.5 versus 0.7%)” now replaces “immune-related AEs (39.7 versus 18.9%) and grade ≥3 infusion reactions (7.5 versus 0.7%).” In the third paragraph of the “Adverse events” subsection, first sentence, the text “infusion reactions (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, irAEs as assessed by the investigator” now replaces “infusion reactions (irAEs) (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, immune-related adverse events.” Further, in Table 2, bottom row “P value” entry, footnote “b” replaces “a”, and in the footnote legend, “a” replaces “*” and “b” replaces “a.” The changes have been made in the online version of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mai, HQ., Chen, QY., Chen, D. et al. Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 28, 214 (2022). https://doi.org/10.1038/s41591-021-01673-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01673-3
This article is cited by
-
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Journal of Hematology & Oncology (2022)